Ethicon pushes for completion of tissue adhesive trials:
This article was originally published in Clinica
Ethicon has given Protein Polymer Technologies until the end of the year to complete trials of its tissue adhesives (see Clinica No 673, p 1). If they are successful, Ethicon will continue to contribute to on-going R&D and regulatory costs. Ethicon and Johnson & Johnson Development, both Johnson & Johnson subsidiaries, have provided an additional $735,000 in R&D expenses. Ethicon has worldwide marketing rights and Johnson & Johnson Development has warrants for some of the biomaterials company's common stock.